Learn more about our company, latest developments in clinical diagnostics, and scientific breakthroughs in the rare disease field. Stay on top, subscribe to our newsletter and follow us on social media.
As part of an exchange with senior business and academic leaders, and state of Mecklenburg-Vorpommern (M-V) government...
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
CENTOGENE, a rare disease company committed to improving the lives of rare disease patients by providing solutions that...
Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development
CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year
2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of...
CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development
NORTHFIELD, IL. — The College of American Pathologists (CAP), a Center for Medicare and Medicaid Services (CMS)-approved...
Provides physicians with virtual encyclopedia of genetic information at their fingertips for improved and efficient...
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification...
